Advanced BioPhotonics, Inc., a development stage company, engages in the development and commercialization of digital imaging technology for the diagnosis and management of various diseases, including cancer and vascular diseases in the United States. Its principal product includes BioScanIR system, which detects diseases that affect the perfusion or reperfusion of blood in tissues and organs. The BioScanIR system assists physicians and researchers in differentiating between normal and abnormal tissues by detecting small changes in perfusion. Advanced BioPhotonics, formerly known as OmniCorder Technologies, Inc., was founded in 1997 and changed its name to Advanced BioPhotonics, Inc. in 2005. The company is headquartered in Bohemia, New York.
Here is what is due Adjunctive screening and detection of breast cancer. The use of the BioScanIR® system as an adjunctive technique in breast cancer detection in certain age categories still holds great promise. This application may be particularly useful in younger women (under 50 years of age) with dense breasts who are at increased risk for breast cancer. We will continue to support the current work being done at the State University of New York Stony Brook in this area. First results should be available in late 2007.
I've tracked the OS 52 MILLION @ .0037 GIVES A MKT CAP OF $192,400.
OS by date On 5/30 it was 38 million on 6/22 39 million 7/10 40 million 9/25 unchanged 11/23 unchanged 11/30 42 million 12/19 52 million Not sure how much if any added today.
It has a 52 week low of .002 and a 52 week high of .08